MAC21 (NCT02927249), A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial, has closed to accrual after completion of target accrual.

Holiday hours and days of operation for the CCTG central office, CCTG’s Tumour Tissue Data Repository and the Bay Area Research Logistics.

Everyone at CCTG would like to congratulate Dr Joseph Connors for his recent appointment to the Order of Canada, as one of 114 Canadian appointees “whose service has shaped our society; whose innovations ignite our imaginations; and whose compassion unites our communities.”  

As with most events in 2020 the 62^nd American Society of Hematology Annual Meeting and Exposition was a virtual meeting held December 5-8. There were four presentations of note for trials that CCTG participated in.

Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from the MAC15 RxPONDER trial presented at the 2020 San Antonio Breast Cancer Symposium.